A new drug for advanced pancreatic cancer has been approved by the Food and Drug Administration. The drug, called daraxonrasib, is a first-of-a-kind pill that blocks a mutated protein fueling tumor growth in most pancreatic cancer cases. It will be sold under the brand name Rasonque by Revolution Medicines.
Patients who took the drug in a study had nearly double the survival time, with fewer severe side effects, compared to those who received chemotherapy. The study involved 500 patients with metastatic pancreatic cancer. Further details about the drug and the study are available from the source, including information about the company-funded research and the FDA's expedited approval process.
